由于公司本次回购注销部分限制性股票将导致注册资本减少，根据《中华人 民共和国公司法》等相关法律法规的规定，公司特此通知债权人，公司债权人自 接到公司通知之日起 30 日内、未接到通知者自本公告披露之日起 45 日内，均有 权凭有效债权文件及相关凭证要求公司清偿债务或者提供相应担保。债权人如逾 期未向公司申报债权，不会影响其债权的有效性，相关债务（义务）将由公司根 据原债权文件的约定继续履行。债权人未在规定期限内行使上述权利的，本次回 购注销将按法定程序继续实施。公司债权人如要求公司清偿债务或提供相应担保 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-030 黑龙江珍宝岛药业股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原由 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日召开第五届董事会第二十一次会议和第五届监事会第十七次会议，审议通过了 《关于回购注销 2023 年限制性股票激励计划部分限制性股票 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●限制性股票回购数量：623,996 股 ●限制性股票回购价格：8.28 元/股 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日召开第五届董事会第二十一次会议和第五届监事会第十七次会议，审议并通过 了《关于回购注销 2023 年限制性股票激励计划部分限制性股票的议案》。鉴于 公司2024年度业绩未达到2023年限制性股票激励计划（以下简称"本激励计划"） 第二个解除限售期的考核标准，本激励计划第二个解除限售期解除限售条件未成 就，根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）及公司 《黑龙江珍宝岛药业股份有限公司 2023 年限制性股票激励计划（草案）》（以 下简称"《激励计划》"）的有关规定，公司拟对 22 名激励对象持有的已授予 但尚未解除限售的 623,996 股限制性股票进行回购注销。回购价格为根据《激励 计划》规定调整后的价格加上按照中国人民银行同期存款基准利率计算的存款利 息之和。本次回购注销尚需提交公 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于黑龙江珍宝岛药业股份有限公司 2023 年度内控审计报告强调事项段所述事项 影响已消除的专项说明审核报告 中国·北京 BEIJING CHINA 目 录 1、关于黑龙江珍宝岛药业股份有限公司 2023 年内部控制 审计报告强调事项段所述事项影响已消除的专项说明审核报 告 1-2 2、黑龙江珍宝岛药业股份有限公司关于 2023 年度内控审 计报告强调事项段所述事项影响已消除的专项说明 1-2 中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于黑龙江珍宝岛药业股份有限公司 二、注册会计师的责任 我们的责任是在实施审核工作的基础上对专项说明发表审核意见。我们按照 中国注册会计师审计准则的规定执行审核工作。中国注册会计师审计准则要求我 们遵守执业道德守则，计划和实施审核工作，以对专项说明是否不存在重大错报 获取合理保证。 在审核过程中，我们实施了检查有关会 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于黑龙江珍宝岛药业股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 中审亚太审字（2025）005291 号 关于黑龙江珍宝岛药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核报告 中国·北京 BEIJING CHINA 目 录 1、关于黑龙江珍宝岛药业股份有限公司非经营性资金占 用及其他关联资金往来情况汇总表的专项审核报告 1-2 2、上市公司 2024 年度非经营性资金占用及其他关联资金 往来情况汇总表 1-2 中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 黑龙江珍宝岛药业股份有限公司全体股东： 我们接受委托，在审计了黑龙江珍宝岛药业股份有限公司（以下简称"珍宝 岛公司"）2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公 司利润表、合并及公司现金流量表和合并及公司股 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 审 计 报 告 AUDIT REPORT 黑龙江珍宝岛药业股份有限公司 内部控制审计报告 中国·北京 BEIJING CHINA 目 录 1、内部控制审计报告 1-2 黑龙江珍宝岛药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了黑龙江珍宝岛药业股份有限公司（以下简称"珍宝岛公司"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、珍宝岛公司对内部控制的责任 2、黑龙江珍宝岛药业股份有限公司 2024 年度内部控制 评价报告 1-5 中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 内部控制审计报告 中审亚太审字（2025）005288 号 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制 评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是珍宝岛公 司董 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 审 计 报 告 AUDIT REPORT 黑龙江珍宝岛药业股份有限公司 2024 年度财务报表审计 中国·北京 BEIJING CHINA 目 录 | 一、审计报告 | 1-5 | | --- | --- | | 二、已审财务报表 | | | 1．合并资产负债表 | 1-2 | | 2．合并利润表 | 3 | | 3．合并现金流量表 | 4 | | 4．合并股东权益变动表 | 5-6 | | 5．资产负债表 | 7-8 | | 6．利润表 | 9 | | 7．现金流量表 | 10 | | 8．股东权益变动表 | 11-12 | | 9．财务报表附注 | 13-137 | 中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 审 计 报 告 中审亚太审字（2025）005287 号 黑龙江珍宝岛药业股份有限公司全体股东： 一、审计意见 我们审计了黑龙江珍宝岛药业 ...

北京市兰台律师事务所 关于 黑龙江珍宝岛药业股份有限公司 回购注销 2023 年限制性股票激励计划 部分限制性股票的 法律意见书 地址:北京市朝阳区曙光西里甲1号第三置业B座29层 电话: （8610）52287799 传真: （8610）58220039 邮编: 100028 网址：www.lantai.cn 二〇二五年四月 法律意见书 北京市兰台律师事务所 关于黑龙江珍宝岛药业股份有限公司 回购注销 2023 年限制性股票激励计划部分限制性股票的 法律意见书 兰台意字(2025) 第 1951 号 致:黑龙江珍宝岛药业股份有限公司 北京市兰台律师事务所(以下简称"兰台"或"本所")接受黑龙江珍宝岛 药业股份有限公司(以下简称"公司"或"珍宝岛")的委托,作为公司 2023 年限制性股票激励计划(以下简称"本次股权激励计划")的特聘专项法律顾问。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委员会 〈以下简称"中国证监会"〉《上市公司股权激励管理办法》(以下简称"《管 理办法》")及其他有关法律、法规和规范性文件,及《 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于黑龙江珍宝岛药业股份有限公司 募集资金年度存放与实际使用情况 的鉴证报告 中国·北京 BEIJING CHINA 目 录 1、关于黑龙江珍宝岛药业股份有限公司募集资金年度存 放与实际使用情况的鉴证报告 1-2 2、黑龙江珍宝岛药业股份有限公司关于 2024 年度募集资 金存放与实际使用情况的专项报告 1-9 中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 关于黑龙江珍宝岛药业股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 中审亚太审字（2025）005289 号 黑龙江珍宝岛药业股份有限公司全体股东： 我们接受委托，对后附的黑龙江珍宝岛药业股份有限公司（以下简称"珍宝 岛公司"）截至 2024 年 12 月 31 日止的《董事会关于公司募集资金年度存放与 实际使用情况的专项报告》进行了鉴证工作。 按照中国证监会发布的《上市公司监管指引第 2 ...

Financial Performance - The company's operating revenue for 2024 was CNY 2,703,934,334.17, a decrease of 13.84% compared to 2023[20]. - The net profit attributable to shareholders for 2024 was CNY 438,216,195.63, down 7.30% from the previous year[20]. - The net profit after deducting non-recurring gains and losses increased significantly to CNY 402,967,474.16, compared to a loss of CNY 31,842,460.08 in 2023, marking a 1,365.50% increase[20]. - The net cash flow from operating activities improved to CNY 164,308,401.91, a 134.36% increase from the previous year[20]. - The total assets at the end of 2024 were CNY 12,712,631,463.50, reflecting a 1.98% increase from 2023[20]. - The basic earnings per share for 2024 was CNY 0.4662, a decrease of 7.35% compared to 2023[21]. - The weighted average return on equity decreased to 5.70%, down 0.76 percentage points from the previous year[21]. - The company achieved operating revenue of 2.704 billion yuan and a net profit attributable to shareholders of 438 million yuan for the reporting period[29]. - The company’s main business revenue for the reporting period was 2.677 billion RMB, a year-on-year decrease of 13.20%, while the main business cost was 1.186 billion RMB, a year-on-year decrease of 33.10%[112]. - The total cost for the current period is CNY 1,186,321,312.29, a decrease of 33.10% compared to CNY 1,773,283,468.40 in the same period last year[121]. Dividend Distribution - The company plans to distribute a cash dividend of 1.50 yuan per 10 shares, totaling approximately 141.13 million yuan, which accounts for 32.21% of the net profit attributable to ordinary shareholders[4]. - The total share capital as of December 31, 2024, is 941,140,609 shares, with 940,859,283 shares eligible for the dividend distribution after accounting for treasury shares[4]. - The company does not plan to issue bonus shares or convert reserves into share capital in this profit distribution[4]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[6]. - The company has not faced any non-operational fund occupation by controlling shareholders or related parties[5]. - There are no violations of decision-making procedures regarding external guarantees[5]. - The company has detailed various risks and countermeasures in the management discussion and analysis section of the report[6]. Audit and Compliance - The company has received a standard unqualified audit report from Zhongshun Yatai Accounting Firm[3]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[3]. - The company has not disclosed any significant changes in its operational address or registration during the reporting period[16]. Research and Development - The company is focusing on R&D in traditional Chinese medicine, particularly in cardiovascular, digestive, respiratory, and immune treatment areas, with ongoing clinical evaluations and quality standard improvements[57]. - The company has completed preclinical research for its 1.1 class innovative traditional Chinese medicine (TCM) drug, receiving clinical trial approval from the regulatory authority[151]. - The company has five formulation projects that have obtained production approval and three projects that have completed registration applications during the reporting period[152]. - The company has initiated phase I clinical trials for its innovative drug HZB1006, a second-generation FGFR inhibitor, which has shown promising progress[152]. - The company is actively collaborating with renowned universities and research institutions to enhance its TCM research capabilities, focusing on areas such as cardiovascular, respiratory, and oncology diseases[151]. - The company has established a comprehensive R&D incubation park covering TCM, chemical drugs, and biological drugs to support pharmaceutical technology needs[150]. - The company has a total of 14 ongoing R&D projects, including both innovative and second-development drugs, with various stages of clinical trials[153]. Market Strategy - The company aims to expand its product market share through strategic participation in national centralized procurement, with 14 product specifications selected for 2025, providing more high-quality medication options[79]. - The marketing strategy emphasizes a comprehensive coverage of sales management systems across various medical institutions and retail markets, driving marketing performance[78]. - The company is focusing on the outpatient market as a new growth engine, adapting to policy changes and reshaping its business model to meet diverse market needs[183]. - The company aims to achieve its annual targets by customizing marketing plans for each business unit, focusing on "broad coverage, deep penetration, and precise output" for 2025 core performance indicators[195]. - The company is focusing on a multi-channel marketing strategy, targeting high-quality medical institutions and retail chains[161]. Product Development and Innovation - The company has completed acquisitions of 23 products, including Dan Ning Pian and An Gong Niu Huang Wan, enhancing its product pipeline and clinical competitiveness[56]. - The company is exploring international market opportunities by seeking collaborations on innovative and generic drug projects that align with its strategic development direction[150]. - The company plans to acquire complementary products in major disease treatment areas to inject new growth momentum into its future development[188]. - The company is committed to quality control and safety in drug production, adhering to strict quality standards and regulatory requirements throughout the drug lifecycle[84]. Industry Trends - The pharmaceutical industry saw a 3.4% year-on-year increase in value added for large-scale enterprises, with total revenue for the industry remaining flat at 2.976 trillion yuan[37]. - The traditional Chinese medicine industry is experiencing a profound transformation from scale expansion to quality-driven growth, with the industrial output value accounting for 24.1% of the pharmaceutical industry's revenue in 2023[36]. - The overall pharmaceutical market is expected to grow at a rate of 7%-8%, slightly above China's GDP growth forecast of approximately 5.2%[139]. - The aging population in China is projected to exceed 420 million by 2035, leading to an increased demand for chronic disease management, which presents significant opportunities for traditional Chinese medicine[182]. Awards and Recognition - The company has been recognized with multiple awards, including the "Five-Star Brand" and "Five-Star After-Sales Service" certifications, highlighting its brand and service excellence[49]. - The company has been recognized with multiple awards, including "Most Investment Value Listed Company" and "Corporate Social Responsibility Award" for its brand value[104]. - The company ranked among the top 30 traditional Chinese medicine listed companies in 2024, highlighting its competitive position in the industry[34].

黑龙江珍宝岛药业股份有限公司2025 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 证券代码：603567 证券简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2025 年第一季度报告 | 项目 | 本报告期 | 上年同期 | 本报告期比上年同 | | --- | --- | --- | --- | | | | | 期增减变动幅度(%) | | 营业收入 | 468,943,569.26 | 1,117,297,002.98 | -58.03 | | 归属于上市公司股东的净 | 75,295,443.26 | 293,365,824.9 ...